Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.

Results from the multicentre randomized trial of CHART (continuous, hyperfractionated, accelerated radiotherapy) in non-small-cell lung cancer (NSCLC) showed a significant increase in survival (P=0.004) compared with conventional radiotherapy and a therapeutic benefit relative to late radiation-indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, M. I., Rojas, A., Lyn, B. E., Pigott, K., Powell, M., Goodchild, K., Hoskin, P. J., Phillips, H., Verma, N.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063173/
https://www.ncbi.nlm.nih.gov/pubmed/9823973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063173/
https://www.ncbi.nlm.nih.gov/pubmed/9823973

Ejemplares similares